Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOHealthcare · Biotechnology
+2.61%$3.14
AH$3.14+0.00%vs close
Mkt Cap-
Float81.79M
O/S-
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$99.96M
Total Assets$268.69M
Free Cash Flow-$98.96M
Debt & Equity
Debt 3%
Equity 97%
Total Debt$7.89M
Total Equity$246.67M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in LXEO's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$268.69M
Liabilities$22.02M
Accounts Receivable$0
Accounts Payable$4.86M
Inventory$0
PP&E (Net)$8.86M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $654K | $1.66M | $518K |
| YoY Growth | - | - | - | -60.5% | 219.6% | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $654K | $1.66M | $518K |
| Gross Margin | - | - | - | 100.0% | 100.0% | 100.0% |
| Research and Development | $63.8M | $74.09M | $53.13M | $49.16M | $45.12M | $4.32M |
| Selling, General, and Administrative | $45.46M | $31.68M | $15.38M | $12M | $7.17M | $787K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $109.26M | $105.77M | $68.51M | $61.16M | $52.29M | $5.11M |
| Operating Income (EBIT) | -$109.26M | -$105.77M | -$68.51M | -$60.51M | -$50.64M | -$4.59M |
| Operating Margin | - | - | - | -9252.1% | -3055.9% | -884.9% |
| Interest Expense | $206K | $114K | $205K | $91K | $0 | $147K |
| Interest Income | $6.13M | $7.56M | $2.87M | $1.32M | $15K | $0 |
| Other Income (Expense) | $9.3M | $7.43M | $2.12M | $1.23M | $15K | -$565K |
| Income Before Tax (EBT) | -$99.96M | -$98.33M | -$66.39M | -$59.28M | -$50.62M | -$5.15M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$99.96M | -$98.33M | -$66.39M | -$59.28M | -$50.62M | -$5.15M |
| Net Income Margin | - | - | - | -9063.8% | -3055.0% | -993.8% |
| Supplementary Data | ||||||
| EPS | -1.86 | -3.09 | -2.49 | -2.36 | -2.01 | -0.20 |
| Diluted EPS | -1.86 | -3.09 | -2.49 | -2.40 | -2.01 | -0.20 |
| Weighted Average OS | 53.65M | 31.79M | 26.65M | 25.17M | 25.17M | 25.17M |
| EBITDA | -$97.68M | -$96.19M | -$64.35M | -$58.04M | -$50.61M | -$4.59M |
| EBITDA Margin | - | - | - | -8874.8% | -3054.3% | -884.9% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $63M | $35.01M | $121.47M | $77.33M | $135.86M | $29.37M |
| Short-Term Investments | $118.77M | $86.5M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $181.77M | $121.52M | $121.47M | $77.33M | $135.86M | $29.37M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $6.63M | $4.6M | $3K | $371K | $696K | $34K |
| Total Current Assets | $188.39M | $126.12M | $124.29M | $80.05M | $136.68M | $29.41M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $8.86M | $10.56M | $12.26M | $13.78M | $174K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $68.19M | $7.01M | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.25M | $3.25M | $3.25M | $7.49M | $2K | $3K |
| Total Long-Term Assets | $80.3M | $20.82M | $15.51M | $21.26M | $176K | $3K |
| Other Assets | $0 | $0 | $0 | -$4.23M | $0 | $0 |
| Total Assets | $268.69M | $146.94M | $139.81M | $97.08M | $136.86M | $29.41M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $4.86M | $6.42M | $3.79M | $2.68M | $3.06M | $44K |
| Short-Term Debt | $0 | $2.67M | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $157K | $506K | $528K | $38K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $46K | $140K |
| Other Current Liabilities | $4.14M | $4.66M | $3.36M | $2.15M | $961K | $1K |
| Total Current Liabilities | $16.81M | $22.85M | $17.24M | $14.35M | $7.45M | $698K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $185.03M | $185.01M | $34.25M |
| Total Long-Term Liabilities | $5.21M | $7.25M | $9.03M | $195.68M | $185.01M | $34.25M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $22.02M | $30.1M | $26.27M | $210.03M | $192.46M | $34.95M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $185.01M | $0 |
| Common Stock | $7K | $3K | $3K | $0 | $2K | $2K |
| Retained Earnings | -$380.13M | -$280.17M | -$181.84M | -$115.45M | -$56.17M | -$5.55M |
| Comprehensive Income & Other | $188K | -$103K | $0 | -$185.03M | -$185.01M | $0 |
| Other Stockholders' Equity | $626.8M | $397.01M | $295.37M | $2.49M | $566K | $10K |
| Total Equity | $246.67M | $116.84M | $113.53M | -$112.95M | -$55.6M | -$5.54M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $268.69M | $146.94M | $139.81M | $97.08M | $136.86M | $29.41M |
| Supplementary Data | ||||||
| Total Debt | $7.89M | $9.92M | $11.64M | $13.48M | $0 | $0 |
| Net Debt | -$55.11M | -$25.09M | -$109.83M | -$63.85M | -$135.86M | -$29.37M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$99.96M | -$98.33M | -$66.39M | -$59.28M | -$50.62M | -$5.15M |
| Depreciation & Amortization | $2.08M | $2M | $1.84M | $1.15M | $13K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $12.13M | $12.47M | $3.04M | $1.78M | $386K | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.56M | $2.38M | -$180K | -$426K | $3.02M | $44K |
| Other Working Capital | -$7.95M | $351K | $1.66M | $2.22M | $3.03M | $106K |
| Total Working Capital Change | -$9.52M | $2.73M | $1.48M | $1.79M | $6.04M | $150K |
| Other Non-Cash Items | -$3.3M | -$23K | $530K | $0 | $0 | $1.87M |
| Net Cash from Operating | -$98.56M | -$81.15M | -$59.5M | -$54.56M | -$44.18M | -$3.13M |
| Investing Activities | ||||||
| Capital Expenditures | -$397K | -$481K | -$115K | -$672K | -$188K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$195.4M | -$93.6M | $0 | $0 | $0 | $0 |
| Sales of Investments | $105.53M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $17K | $0 | -$50K | -$229K | $0 | $0 |
| Net Cash from Investing | -$90.25M | -$94.08M | -$165K | -$901K | -$188K | $0 |
| Financing Activities | ||||||
| Debt Repaid | $533K | $410K | -$3.58M | $163K | - | -$2.6M |
| Common Stock Issuance | $217.33M | $88.71M | $100.25M | $332K | $170K | $0 |
| Common Stock Repurchases | $0 | -$17K | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $491K | -$35K | $0 | -$203K | -$224K |
| Net Cash from Financing | $216.79M | $88.78M | $103.79M | $189K | $150.86M | $32.38M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $27.98M | -$86.45M | $44.13M | -$55.27M | $106.49M | $29.25M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$98.56M | -$81.15M | -$59.5M | -$54.56M | -$44.18M | -$3.13M |
| Capital Expenditure | -$397K | -$481K | -$165K | -$901K | -$188K | $0 |
| Free Cash Flow | -$98.96M | -$81.63M | -$59.66M | -$55.46M | -$44.37M | -$3.13M |
| Cash at Beginning | $38.27M | $124.72M | $80.59M | $135.86M | $29.37M | $128K |
| Cash at End | $66.25M | $38.27M | $124.72M | $80.59M | $135.86M | $29.37M |